PRESIDENT HAS SERVED AS A REVIEWER FOR THE BST-F (80) BIOENGINEERING ‘ACADEMIC RESEARCH ENHANCEMENT AWARD’ STUDY SECTION FOR THE NIH

PDX Pharma’s President has served as a reviewer for the BST-F (80) Bioengineering ‘Academic Research Enhancement Award’ Study Section for the National Institute of Health (NIH) held on March 9, 2017.

pdx news

  • PDX Pharma awarded two-year $1.87M phase II SBIR grant from the National Cancer Institute (NCI) for the development of ARAC-02, a novel lung cancer treatment

    2/21/2023
    read more

  • PDX Pharma’s ARAC-02 drug candidate has been selected into the Nanotechnology Characterization Lab (NCL)’s collaboration and characterization program.

    1/5/2023
    read more

  • PDX Pharma won two Corporate Philanthropy Awards

    11/2/2022
    read more

Copyright © 2017 PDX Pharmaceuticals, Inc. All rights reserved